EC approves Cabotegravir LA by ViiV Healthcare for HIV prevention

Pallavi Madhiraju- September 19, 2023 0

ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced that the European Commission (EC) has authorized Apretude, also known as cabotegravir ... Read More

Strides Pharma’s HIV generic drug gets tentative FDA approval

Pallavi Madhiraju- September 14, 2023 0

Strides Pharma Science Limited (Strides) announced that its Singapore-based stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, has received tentative approval for Dolutegravir 50mg ... Read More

Aurobindo Pharma gets tentative FDA approval for generic HIV treatment for children

Pallavi Madhiraju- August 16, 2023 0

Aurobindo Pharma Limited has achieved a significant milestone by securing the US Food and Drug Administration (FDA)'s tentative nod under the PEPFAR program for its ... Read More

Lupin gains tentative FDA approval for Dolutegravir Tablets generic

Pallavi Madhiraju- July 5, 2023 0

Indian pharmaceutical company Lupin announced that the US Food and Drug Administration (FDA) has granted tentative approval for its Abbreviated New Drug Application (ANDA) for ... Read More

ViiV Healthcare secures Cabenuva FDA approval for HIV-1 treatment

pharmanewsdaily- January 24, 2021 0

Cabenuva FDA approval : ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its long-acting regimen Cabenuva for the treatment ... Read More

ViiV Healthcare bags Rukobia FDA approval for HIV patients with limited treatment options

pharmanewsdaily- July 4, 2020 0

Rukobia FDA approval : ViiV Healthcare said that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets as a ... Read More

ViiV Healthcare secures Dovato EMA approval for HIV-1 treatment

pharmanewsdaily- July 14, 2019 0

Dovato EMA approval : The European Commission (EC) has approved ViiV Healthcare’s once-daily, single-pill, two-drug regimen Dovato (dolutegravir/lamivudine) for the treatment of human immunodeficiency virus ... Read More

FDA approves ViiV Healthcare’s Juluca for maintenance treatment of HIV-1

pharmanewsdaily- November 25, 2017 0

ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK), Pfizer, and Shionogi, has received approval from the U.S. Food and Drug Administration (FDA) for its two-drug ... Read More